Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

REP. WYDEN TO PRESS FOR TAXOL COST DATA during Jan. 25 hearing before the Oregon Democrat's House Small Business/Regulation Subcommittee. Wyden wants to determine how Bristol-Myers Squibb and the National Cancer Institute arrived at their agreement on the pricing of the NCI-developed anticancer agent. Because cost information has not been made public, the congressman says it is impossible to know whether Taxol is priced fairly. National Institutes of Health Director Bernadine Healy, MD, and NCI Cancer Treatment Division Director Bruce Chabner, MD, have been invited to testify. Bristol was also invited to testify: VP- Licensing Z. P. Horovitz, a veteran of previous Taxol hearings, is expected to represent the company. Bristol has provided generalized information of the factors involved in the Taxol pricing decision. The company resisted making any specific cost data on the product available and will continue to try to protect those data. Another witness is expected to be Jamie Love, director of a consumer group called the Taxpayer Assets Foundation. Love is expected to argue that taxpayers' investment in Taxol development, in the form of NCI research, should yield a return reflected in as low a market price as possible. FDA approved Taxol (paclitaxel) for treatment of refractory ovarian cancer Dec. 29 ("The Pink Sheet" Jan. 4, p. 8). The cost for an average three-week treatment cycle with Bristol-Myers Squibb's antitumor agent is $986.18; patients will require two to six cycles. However, the company notes that the net average cost for a cycle is $695.25, factoring for Medicaid rebates, free supplies for NCI and for indigent patients. That pricing -- in the range of existing ovarian cancer treatments -- appeared to satisfy NCI's concerns under the Cooperative Research and Development Agreement. The net weighted average price for Taxol is in the range of two other Bristol anticancer agents: Platinol (cisplatin), which costs about $680 for a one-month supply, and the previously marketed ovarian cancer treatment Paraplatin (carboplatin), which costs about $1,030 for one month's therapy.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts